CORESTEMCHEMON INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,690 KRW | +1.04% |
|
+3.18% | +72.67% |
| Sales 2022 | 46.29B 33.7M 46.02M | Sales 2023 | 33.66B 24.5M 33.46M | Capitalization | 145B 106M 144M |
|---|---|---|---|---|---|
| Net income 2022 | -2.66B -1.93M -2.64M | Net income 2023 | -17.67B -12.87M -17.57M | EV / Sales 2022 | 5.86 x |
| Net Debt 2022 | 15.84B 11.53M 15.75M | Net Debt 2023 | 30.06B 21.89M 29.88M | EV / Sales 2023 | 5.2 x |
| P/E ratio 2022 |
-14
x | P/E ratio 2023 |
-8.09
x | Employees | 376 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 53.1% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.04% | ||
| 1 week | +3.18% | ||
| Current month | +8.34% | ||
| 1 month | +7.94% | ||
| 3 months | +66.05% | ||
| 6 months | +117.29% | ||
| Current year | +72.67% |
1 week
11 420.00
12 380.00
1 month
9 600.0013 440.00
Current year
6 490.0013 440.00
1 year
5 250.0013 440.00
3 years
5 250.0024 800.00
5 years
5 250.0034 350.00
10 years
5 250.0048 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gyeong-Sook Kim
CEO | Chief Executive Officer | 59 | - |
Tae-Yong Lee
CTO | Chief Tech/Sci/R&D Officer | 42 | - |
Heon-Jeong Lim
AUD | Comptroller/Controller/Auditor | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gyeong-Sook Kim
CEO | Chief Executive Officer | 59 | - |
Kwan-Hee Hong
BRD | Director/Board Member | 65 | 18-02-28 |
Sang-Bae Han
BRD | Director/Board Member | 59 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-28 | 11,690 | +1.04% | 164 373 |
| 24-04-26 | 11,570 | -1.78% | 182,253 |
| 24-04-25 | 11,780 | -0.76% | 188,069 |
| 24-04-24 | 11,870 | +1.45% | 306,027 |
| 24-04-23 | 11,700 | -1.02% | 217,246 |
End-of-day quote Korea S.E., April 28, 2024
More quotes
Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +72.67% | 180M | |
| +2.45% | 42.75B | |
| +47.70% | 41.61B | |
| +11.95% | 41.34B | |
| -8.83% | 26.59B | |
| +7.10% | 25.49B | |
| -22.69% | 18.12B | |
| +30.49% | 12.24B | |
| -2.14% | 11.76B | |
| +9.22% | 11B |
- Stock Market
- Equities
- A166480 Stock
